Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner
Spotify%20--%3e%3csvg%20version='1.1'%20id='Livello_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20width='300px'%20height='300px'%20viewBox='0%200%20300%20300'%20enable-background='new%200%200%20300%20300'%20xml:space='preserve'%3e%3cg%20id='XMLID_632_'%3e%3clinearGradient%20id='XMLID_2_'%20gradientUnits='userSpaceOnUse'%20x1='150'%20y1='0'%20x2='150'%20y2='300'%3e%3cstop%20offset='0'%20style='stop-color:%23F452FF'/%3e%3cstop%20offset='1'%20style='stop-color:%23832BC1'/%3e%3c/linearGradient%3e%3cpath%20id='XMLID_662_'%20fill-rule='evenodd'%20clip-rule='evenodd'%20fill='url(%23XMLID_2_)'%20d='M294.1,260c-2.9,7.4-9.6,17.8-19.2,25.2%20c-5.5,4.2-12.1,8.3-21.1,11c-9.6,2.9-21.5,3.8-36.3,3.8h-135c-14.8,0-26.6-1-36.3-3.8c-9-2.7-15.6-6.7-21.1-11%20c-9.5-7.3-16.3-17.8-19.2-25.2C0.1,245.1,0,228.2,0,217.5l0,0v-135l0,0C0,71.8,0.1,54.9,5.9,40c2.9-7.4,9.6-17.8,19.2-25.2%20c5.5-4.2,12.1-8.3,21.1-11C55.9,1,67.7,0,82.5,0l0,0h135l0,0c14.8,0,26.6,1,36.3,3.8c9,2.7,15.6,6.7,21.1,11%20c9.5,7.3,16.3,17.8,19.2,25.2c5.9,14.9,5.9,31.9,5.9,42.5v135C300,228.2,299.9,245.1,294.1,260z'/%3e%3cg%3e%3cpath%20id='XMLID_657_'%20fill='%23FFFFFF'%20d='M175.7,181.1c-0.4-3.6-1.6-6.2-4-8.6c-4.5-4.7-12.4-7.8-21.7-7.8c-9.3,0-17.2,3-21.7,7.8%20c-2.3,2.5-3.6,5-4,8.6c-0.8,7-0.3,13,0.5,22.7c0.8,9.2,2.3,21.5,4.2,33.9c1.4,8.9,2.5,13.7,3.5,17.1c1.7,5.6,7.8,10.4,17.5,10.4%20c9.7,0,15.9-4.9,17.5-10.4c1-3.4,2.1-8.2,3.5-17.1c1.9-12.5,3.4-24.7,4.2-33.9C176.1,194.1,176.5,188.1,175.7,181.1z'/%3e%3cpath%20id='XMLID_655_'%20fill='%23FFFFFF'%20d='M174.6,130.1c0,13.6-11,24.6-24.6,24.6s-24.6-11-24.6-24.6c0-13.6,11-24.6,24.6-24.6%20S174.6,116.6,174.6,130.1z'/%3e%3cpath%20id='XMLID_653_'%20fill='%23FFFFFF'%20d='M149.7,33.2C92.3,33.4,45.3,80,44.5,137.4c-0.6,46.5,29.1,86.3,70.6,100.9%20c1,0.4,2-0.5,1.9-1.5c-0.5-3.6-1.1-7.2-1.5-10.8c-0.2-1.3-1-2.3-2.1-2.9c-32.8-14.3-55.7-47.2-55.3-85.3%20c0.5-50,41.3-90.7,91.2-91.1c51.1-0.4,92.8,41,92.8,92c0,37.7-22.8,70.1-55.3,84.4c-1.2,0.5-2,1.6-2.1,2.9%20c-0.5,3.6-1,7.2-1.5,10.8c-0.2,1.1,0.9,1.9,1.9,1.5c41.1-14.4,70.6-53.6,70.6-99.6C255.5,80.5,208,33.1,149.7,33.2z'/%3e%3cpath%20id='XMLID_651_'%20fill='%23FFFFFF'%20d='M147.3,68.2c-37.4,1.4-67.4,32.3-67.9,69.7c-0.3,24.6,12,46.4,30.9,59.3%20c0.9,0.6,2.2-0.1,2.2-1.2c-0.3-4.3-0.3-8.1-0.1-12.1c0.1-1.3-0.4-2.5-1.4-3.4c-11.5-10.8-18.5-26.2-18.1-43.2%20c0.8-30,24.9-54.4,54.9-55.6c32.6-1.3,59.4,24.9,59.4,57.1c0,16.4-7,31.2-18.1,41.7c-0.9,0.9-1.4,2.1-1.4,3.4%20c0.2,3.9,0.1,7.7-0.1,12c-0.1,1.1,1.2,1.9,2.2,1.2c18.6-12.7,30.9-34.2,30.9-58.4C220.8,98.9,187.5,66.6,147.3,68.2z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Apple PodcastsAbout 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target this mutation and even more progress is occurring with newer drugs and various treatment combinations in clinical trials.
Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, will summarize key developments and clinical trials currently underway for FLT3 positive AML. If you have a FLT3 mutation, this radio show episode is definitely for you.
Margaret Kasner, MD
Sidney Kimmel Cancer Center
Interview Date: February 7th, 2022
About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target this mutation and even more progress is occurring with newer drugs and various treatment combinations in clinical trials.
In this show, Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, summarizes key developments and clinical trials currently underway for FLT3 positive AML.
Thanks to Our Episode Sponsor
Katie Braswell
Katie joined HealthTree as the Community Director for AML in 2021 and became HealthTree's Director of Education in 2023.
Margaret Kasner, MD